While a recent study from Denmark could not identify a statistically significant correlation between FGFR3 amplifications or mutations to PD-L1 expression in primary urothelial carcinomas [58], Sweis et al. showed that an activated FGFR3 pathway is linked to non-T-cell-inflamed tumors, which are characterized by poorer prognosis and resistance to immune checkpoint inhibitors [56]. Here, CD274 is linked to urothelial carcinoma.